This report was first published by Endpoints News. To see the original version, click here
A few years ago, the oncology world wondered if it had found its next big breakthrough: a third major checkpoint inhibitor beyond PD-1 and CTLA-4.
The FDA in 2022 approved Bristol Myers Squibb’s LAG-3-targeting Opdualag. Many drugmakers hoped that would be the start of a new class of cancer immunotherapy. But there have been few positive updates in the LAG-3 world since then.
您已阅读18%（467字），剩余82%（2060字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。